The use of which of the following helps in reducing the toxicity of Doxorubicin to the hea
**Core Concept**
Doxorubicin is an anthracycline antibiotic that intercalates DNA strands, inhibiting the progression of topoisomerase II and inducing apoptosis in cancer cells. However, its use is limited by cardiotoxicity, which is mediated by the generation of reactive oxygen species (ROS) and the disruption of mitochondrial function.
**Why the Correct Answer is Right**
The use of Dexrazoxane (also known as ICRF-187) helps in reducing the toxicity of Doxorubicin to the heart by forming a complex with iron, thereby inhibiting the formation of ROS and subsequently reducing the cardiotoxic effects of Doxorubicin. This is achieved through the chelation of iron, which is essential for the Fenton reaction, a process that generates ROS. By preventing the formation of ROS, Dexrazoxane protects the heart from damage caused by Doxorubicin.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it does not address the specific mechanism of Doxorubicin cardiotoxicity. While antioxidants may have some protective effects, they do not specifically target the iron-mediated Fenton reaction.
**Option B:** This option is incorrect because it does not have a direct role in reducing Doxorubicin cardiotoxicity. While certain cardioprotective agents may have some benefits, they are not specifically indicated for reducing Doxorubicin toxicity.
**Option C:** This option is incorrect because it is not a known agent for reducing Doxorubicin cardiotoxicity. In fact, some agents may even increase the risk of cardiotoxicity.
**Clinical Pearl / High-Yield Fact**
Dexrazoxane is a cardioprotective agent that should be considered in patients receiving high-dose Doxorubicin therapy. Its use can help reduce the risk of heart failure and other cardiotoxic effects associated with Doxorubicin.
**Correct Answer:** C. Dexrazoxane.